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Mitochondrial redox imbalance has been implicated in mechanisms of aging, various
degenerative diseases and drug-induced toxicity. Statins are safe and well-tolerated
therapeutic drugs that occasionally induce myotoxicity such as myopathy and
rhabdomyolysis. Previous studies indicate that myotoxicity caused by statins may be
linked to impairment of mitochondrial functions. Here, we report that 1-h incubation
of permeabilized rat soleus muscle fiber biopsies with increasing concentrations of
simvastatin (1–40μM) slowed the rates of ADP-or FCCP-stimulated respiration supported
by glutamate/malate in a dose-dependent manner, but caused no changes in resting
respiration rates. Simvastatin (1μM) also inhibited the ADP-stimulated mitochondrial
respiration supported by succinate by 24% but not by TMPD/ascorbate. Compatible
with inhibition of respiration, 1μM simvastatin stimulated lactate release from soleus
muscle samples by 26%. Co-incubation of muscle samples with 1mM L-carnitine, 100μM
mevalonate or 10μM coenzyme Q10 (Co-Q10) abolished simvastatin effects on both
mitochondrial glutamate/malate-supported respiration and lactate release. Simvastatin
(1μM) also caused a 2-fold increase in the rate of hydrogen peroxide generation and
a decrease in Co-Q10 content by 44%. Mevalonate, Co-Q10 or L-carnitine protected
against stimulation of hydrogen peroxide generation but only mevalonate prevented the
decrease in Co-Q10 content. Thus, independently of Co-Q10 levels, L-carnitine prevented
the toxic effects of simvastatin. This suggests that mitochondrial respiratory dysfunction
induced by simvastatin, is associated with increased generation of superoxide, at
the levels of complexes-I and II of the respiratory chain. In all cases the damage
to these complexes, presumably at the level of 4Fe-4S clusters, is prevented by
L-carnitine.
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INTRODUCTION
Statins are natural (fungal-derived) or synthetic inhibitors of the
enzyme HMG-CoA reductase that catalyzes the conversion of 3-
hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) into meval-
onic acid, the rate-limiting step in cholesterol synthesis (Endo,
1992). High plasma levels of cholesterol are well established
as independent risk factor for coronary heart disease (Sirvent
et al., 2005a) that can be significantly reduced by statins treat-
ment (Tobert et al., 1982). The efficacy and tolerability of statins
are well documented (Tobert et al., 1982; Sirvent et al., 2005b).
Although this treatment normally lowers morbidity andmortality
(LIPID Study Group, 1998) about 10% of the patients (Bruckert
et al., 2005) developmyophatic symptoms and approximately one
in 7.5 million patients develop fatal rhabdomyolysis (Venero and
Thompson, 2009). Myopathic symptoms caused by statins, such
as muscle cramps, myalgia, weakness and exercise intolerance can
occur with or without increase in plasma creatine kinase levels
(Sirvent et al., 2005a).
Statins block cholesterol synthesis early in its metabolic
pathway therefore they also decrease the production of both
ubiquinone (Co-Q10) and other important metabolites including
dolichols and other prenylated isoprenoids required for mus-
cle cell functions (Sirvent et al., 2008). Co-Q10 is an important
respiratory chain electron transporter that also displays antiox-
idant properties in its reduced form (ubiquinol). Although the
molecular mechanisms underlying statins induced myotoxicity
are not well established the most popular hypothesis proposes
that it is mediated by inhibition of mitochondrial respiration
as a consequence of Co-Q10 depletion (Ghirlanda et al., 1993;
Laaksonen et al., 1995; Thibault et al., 1996; Miyake et al., 1999;
Rundek et al., 2004; Paiva et al., 2005; Littarru and Langsjoen,
2007; Mabuchi et al., 2007; Young et al., 2011; Bookstaver et al.,
2012). In addition, several studies using isolated mitochondria or
intact cells propose that statins promote cell death mediated by
mitochondrial dysfunctions associated with alterations in calcium
homeostasis, inhibition of beta-oxidation, inhibition of complex I
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of the electron transport chain andmitochondrial oxidative stress
(Sirvent et al., 2005b; Yasuda et al., 2005; Kaufmann et al., 2006;
Velho et al., 2006; Oliveira et al., 2008; Skottheim et al., 2008;
Itagaki et al., 2009; Kwak et al., 2012).
Data from our group (Velho et al., 2006) showed that statins
stimulate Ca2+ induced mitochondrial permeability transition
(MPT) in vitro, in mitochondria isolated from control mice
liver or in liver mitochondria isolated from mice treated with
lovastatin (100mg/kg daily via gavage, during 15 days). In addi-
tion, Sacher et al. (2005) reported that simvastatin or lovastatin
(1–100μM) activate the mitochondrial pathway of apoptosis
in primary human skeletal muscle cells obtained from skele-
tal muscle biopsies of healthy individuals. With respect to the
mechanisms of cell death induced by statins, we have previously
shown that, at low concentrations (≤10μM), simvastatin induces
apoptosis in PC3 prostate cancer cells. At these low concentra-
tions mevalonate but not cyclosporine A, an inhibitor of MPT,
prevented cell death (Oliveira et al., 2008). At higher concen-
trations (≥60μM) simvastatin-induced necrosis was sensitive to
cyclosporine A but not to mevalonate, indicating that, at high
concentrations, the toxicity of statins is not solely the result of
HMG-CoA reductase inhibition. In addition, cell necrosis was
preceded by a threefold increase in the concentration of cytoso-
lic free Ca2+ and MPT (Oliveira et al., 2008). More recently
Costa et al. (2013) provided evidence that simvastatin-induced
MPT and cell necrosis were inhibited by L-carnitine and pirac-
etam in a dose-dependent fashion; when combined, L-carnitine
and piracetam acted at concentrations significantly lower than
they act individually. These results shed new light into both
the cytotoxic mechanisms of high statins concentrations and
the mechanisms underlying the protection against MPT and cell
death by the compounds L-carnitine and piracetam (Costa et al.,
2013).
L-carnitine, beyond the physiological functions on fatty acids
transport across the inner mitochondrial membrane, has the
properties to scavenge reactive oxygen (Gulcin, 2006; Mescka
et al., 2011) and to bind Fe2+ (Gulcin, 2006) a transition metal,
supposed to participate in the mitochondrial oxidative stress that
leads to MPT (Castilho et al., 1995). Therefore, the aims of
this study were double: first, to analyze the events leading to
simvastatin induced skeletal muscle toxicity, at low concentra-
tions (1μM), and second, to better understand the mechanism
underlying mitochondrial protection against reactive oxygen by
L-carnitine or Co-Q10.
The results presented here indicate that simvastatin induced
inhibition of respiration is mediated by the attack of mitochon-
drially generated superoxide radicals to the respiratory chain
complexes I and II probably at the level of 4Fe-4S clusters. In
addition, both L-carnitine and Co-Q10 act directly as radical
scavenger in the protection against simvastatin-induced oxidative
damage to skeletal muscle mitochondria.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
For all experiments, the reagents used were of analytical
grade. Adenosine 5′-diphosphate monopotassium salt dihy-
drate (ADP), adenosine 5′-triphosphate monopotassium salt
dihydrate (ATP), bovine serum albumin (BSA), dimethyl
sulfoxide (DMSO), ethylene-bis(oxyethylenenitrilo)tetraacetic
acid (EGTA), oligomycin, L-glutamic acid, L-malic acid, car-
bonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP),
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
Phospho-creatine, taurine, (2-[N-Morpholino] ethanesulfonic
acid) monohydrate, ascorbic acid, oxaloacetic acid, imidazole,
K-lactobionate, simvastatin, ubiquinone, β-Nicotinadenineamine
dinucleotide were obtained from Sigma-Aldrich (St. Louis, MO,
USA). The ADP, glutamate and malate solutions were prepared
by dissolving the acids in water and adjusting the pH to 7.2
with KOH.
ANIMALS
Wistar female rats with 10–12 weeks of age had access to stan-
dard laboratory rodent chow diet and water ad libitum and
were housed at 22 ± 2◦C on a 12 h light-dark cycle. The exper-
iments were approved by the Committee for Ethics in Animal
Experimentation at the university and are in accordance with the
Guide for the Care and Use of Laboratory Animals published by
the National Academy of Sciences.
SKELETALMUSCLE SAMPLE PREPARATION
Soleus muscle tissues were harvested from rats and placed in
ice-cold relaxing solution [containing 10mM Ca-EGTA buffer
(2.77mM of CaK2EGTA + 7.23mM K2EGTA) free concentra-
tion of calcium 0.1mmol/L, 20mmol/L imidazole, 50mmol/L
K+/4-morpholinoethanesulfonic acid, 0.5mmol/L dithiothre-
itol, 7mmol/L MgCl2, 5mmol/L ATP, 15mmol/L phospho-
creatine, pH 7.1]. Two to three milligram of soleus skeletal
muscle were utilized and individual fiber bundles were sepa-
rated with 2 forceps. Samples were permeabilized for 30min
in ice-cold relaxing solution with saponin (50μg/mL) gently
stirred and washed 3 times with MiR05 medium (60mmol/L
potassium lactobionate, 0.5mmol/L EGTA, 3mmol/L MgCl2,
20mmol/L taurine, 10mmol/L KH2PO4, 20mmol/L HEPES,
110mmol/L sucrose, 1 g/L BSA, pH 7.1) at 4◦C. Samples
were dried with filter paper and weighted (Kuznetsov et al.,
2008).
OXYGEN CONSUMPTIONMEASUREMENTS
Oxygen consumption in permeabilized skeletal muscle tissues
was measured in a medium MiR05 at 37◦C, in the presence
of 10mM glutamate and 5mM malate, or 5mM succinate, or
50μMTMPD plus 2mM ascorbate plus 1μM antimycin A using
a high resolution oxygraph OROBOROS (Innsbruck, Austria).
Simvastatin or Dimetilsulfóxido (DMSO) was incubated by 1 h.
400μMADP, 1μg/mL oligomycin, and 0.2μMFCCPwere added
during experiments (Kuznetsov et al., 2008).
CITRATE SYNTHASE (CS) ACTIVITY
The conversion of oxaloacetate and acetyl-CoA to citrate
and SH-CoA catalyzed by citrate synthase was monitored by
measuring the colorimetric product thionitrobenzoic acid
(Shepherd and Garland, 1969). Soleus skeletal muscle
homogenates (0.5–0.75mg/mL, wet weight) were incubated
at 30◦C in a buffer containing 50mM tris-HCl (pH 8.0),
0.1% Triton X-100, 250μM oxaloacetate, 50μM acetyl-CoA,
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and 100μM 5,5′-dithiobis(2-nitrobenzoic acid). The increase
in absorbance at 412 nm was monitored for 6min using a
microplate reader (Power Wave XS 2, BioTek Instruments,
Winooski, VT, USA).
LACTATE ASSAY
Lactate production was monitored bymeans of changes in NADH
fluorescence. Medium containing 50mM hydroxylamine, 50mM
tris, pH10.0, 800μM NAD+, 40U lactate dehydrogenase and
an aliquot of medium MiR05 containing the non-permeabilized
sample prior incubation with simvastatin or DMSO for 1 h, at
25◦C. Calibration was made by addition of know concentrations
of lactate. A Hitachi F4500 spectrofluorometer operating at exci-
tation and emission wavelengths of 366 and 450 nm, respectively,
was used to measure the changes in NADH fluorescence.
HYDROGEN PEROXIDE RELEASE
Soleus skeletal muscle samples (∼20mg) were pre incubated with
simvastatin or DMSO for 1 h in medium MiR05 plus 10μM
Amplex red (Molecular Probes, Invitrogen, Carlsbad, CA) and
1U/mL horseradish peroxidase. Calibration was made by addi-
tion of known concentrations of hydrogen peroxide. Changes in
fluorescence were monitored using a spectrofluorometer (Hitachi
F4500) operated at excitation and emission wavelengths of 563
and 587 nm, respectively (Anderson and Neufer, 2006).
SAMPLES FOR COENZYME Q10 ASSAY
Standard coenzyme Q10 (≥98%purity) was purchased from
Sigma-Aldrich (USA). HPLC-grade water was prepared using
a MilliQTM System (Millipore Corporation). Methanol HPLC-
grade was purchase from Merck Chemicals (Germany), Ethanol
analytical grade and perchloric acid were purchased from
F. MAIA (Brazil). Benzene (light petroleum) was purchased
from VETEC (Brazil). Samples from soleus skeletal muscle
(around 100mg) from Wistar rats were prepared as previously
described by Redfearn and Whittaker (1966) with modifications
(Redfearn and Whittaker, 1966). Briefly, muscle tissue sam-
ples were homogenized in medium containing 1mL of MiR05
medium, 1mL of 0.6M perchloric acid, and 3mL of cold
methanol. The homogenates were vortexed during 30 s, 5mL of
benzene were added and the samples were vortexed again for
30 s. The samples were centrifuged at 5000× g for 10min (room
temperature). The upper phase was collected and dried under
nitrogen flux. The precipitate obtained was dissolved in 50μL of
hexane.
HPLC ASSAY FOR COENZYME Q
Coenzyme Q10 was determined using a chromatographic system
Shimadzu LC (Japan) in conjunction with a SPD-10A UV-Visible
set to 275 nm. Twenty microliters of the samples in hexane
were injected into the analytical column (Luna 250 × 4.6mm;
C18 (2) 100A; 5μm particle size; Phenomenex®) maintained at
25◦C. Coenzyme Q10 was eluted from the column at a flow
rate of 1.4mL/min using a isocratic mode linear gradient of
methanol:ethanol (65:35). Lower and upper limits of detection
for total coenzyme Q10 were confirmed at the following con-
centrations: 0.167μmol/L and 150μmol/L. The lower and upper
limits of linearity were observed at the following concentrations:
0.5μmol/L and 50.0μmol/L.
STATISTICAL ANALYSES
The results of experiments performed in at least five independent
experiments are displayed as means ± S.E.D and significance was
assessed by ANOVA, followed by the Tukey post-test, or student-
t test with significance level set at p < 0.05 using Sigma Stat 3.1
(Systat, San Jose, CA, USA).
RESULTS
INHIBITION BY SIMVASTATIN OF ADP- OR FCCP-STIMULATED
OXYGEN CONSUMPTION SUPPORTED BY COMPLEX I SUBSTRATES IN
SKELETALMUSCLE FIBERS
In order to investigate the effects of simvastatin on soleus skele-
tal muscle mitochondrial respiration “in vitro” we incubated the
permeabilized bundles for 1 h in the standard incubationmedium
(MiR05) containing increasing concentrations (1, 15, or 40μM)
of simvastatin or 0.1% DMSO as control. Oxygen consumption
supported by 10mM glutamate plus 5mM malate was moni-
tored before and after the sequential additions of 400μM ADP,
1μg/mL oligomycin, and 0.2μMFCCP. Figure 1 shows that sim-
vastatin promoted a dose dependent inhibition of ADP- and
FCCP-stimulated respiration but did not affect the rate of rest-
ing respiration (data not shown). The inhibition caused by 1μM
simvastatin was 25 and 27% for ADP- and FCCP-stimulated res-
piration, respectively. The inhibition peaked at 57% in the pres-
ence of 40μM simvastatin for both ADP- and FCCP-stimulated
respiration.
Considering that typically prescribed daily oral doses of statins
20–80mg (Kwak et al., 2012) generate concentration peaks in
skeletal muscle in the range of 2–5μM, we choose the concen-
tration of 1μM simvastatin to perform the next experiments.
FIGURE 1 | Inhibition by simvastatin of ADP- or FCCP-stimulated
oxygen consumption supported by complex I substrates in skeletal
muscle. Skeletal muscle samples were incubated in MiR05 medium in the
presence of 1, 15, and 40μM simvastatin, or DMSO for 1 h. ADP (400μM)
or 1μg/mL oligomycin plus 0.2μM FCCP were added where indicated.
Respiration was supported by 10mM glutamate plus 5mM malate.
∗p < 0.05 vs. control by one-way analysis of variance. N = at least
6 independent experiments.
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INHIBITION BY SIMVASTATIN OF ADP-STIMULATED OXYGEN
CONSUMPTION SUPPORTED BY SUCCINATE
The results on respiratory complex II inhibition by statins
reported in the literature are controversial (Sirvent et al., 2005a,
2012; Bouitbir et al., 2012a). Here we analyzed the effect of 1μM
simvastatin on succinate or TMPD/ascorbate supported respira-
tion. One hour incubation of the skeletal muscle preparation with
1μM simvastatin caused 24% inhibition of ADP-stimulated res-
piration supported by succinate but did not significantly change
the rate of TMPD/ascorbate supported respiration (Figure 2A).
In addition, the citrate synthase activity assay applied to skeletal
muscle tissue incubated during 1 h in the presence of 1μM sim-
vastatin indicated that mitochondrial density and number were
not changed by the statin treatment (Figure 2B).
FIGURE 2 | Inhibition by 1µM simvastatin of ADP-stimulated oxygen
consumption supported by succinate but not by TMPD/ascorbate.
(A) Skeletal muscle samples were incubated in MiR05 medium in the
presence of 1μM simvastatin, or DMSO for 1 h. ADP (400μM) or 1μg/mL
oligomycin plus 0.2μMFCCP were respectively added. The respiration was
supported by 5mM succinate or 5μMTMPDplus 2mM ascorbate plus 1μM
antimycin A. (B) Skeletal muscle homogenateswere incubated at 30◦C in a
buffer containing 50mM tris-HCl (pH 8.0), 0.1% Triton X-100, 250μM
oxaloacetate, 50μM acetyl-CoA, and 100μM5, 5′-dithiobis(2-nitrobenzoic
acid) to assay citrate synthase activity. Prior preparation of homogenates,
skeletal muscle samples were incubated by 1 h in MiR05 medium in
presence of 1μM simvastatin. ∗p < 0.05 vs. control by student t-test. N = at
least 5 independent experiments.
INHIBITION BY 1µM SIMVASTATIN OF ADP- OR FCCP-STIMULATED
OXYGEN CONSUMPTION SUPPORTED BY COMPLEX I SUBSTRATES
WAS PREVENTED BY MEVALONATE, Co-Q10 OR L-carnitine
The first step to elucidate the mechanism of simvastatin induced
skeletal muscle respiration inhibition was the co-incubation with
mevalonate, the product of the reaction catalyzed by the enzyme
HMG-CoA reductase. Figures 3A,B show that 100μM meval-
onate protected against simvastatin-induced inhibition of com-
plex I substrates supported respiration stimulated by ADP or
FCCP, respectively. The next step was the co-incubation with
coenzyme Q10, another product of cholesterol de novo biosyn-
thesis. It can be seen that 10μM Co-Q10 similarly to mevalonate
significantly protected against the inhibition of complex I respira-
tion stimulated by ADP- or FCCP (Figures 3A,B). L-carnitine is
another compound reported to protect skeletal muscle or tumor
FIGURE 3 | Inhibition by 1µM simvastatin of (A) ADP or (B)
FCCP-stimulated oxygen consumption supported by complex I
substrates was prevented by mevalonate, Co-Q10 or L-carnitine.
Skeletal muscle samples were incubated in MiR05 medium in the presence
of 1μM simvastatin, or DMSO for 1h containing 100μM mevalonate,
10μM coenzyme Q10, or 1mM L-carnitine. ADP (400μM) or 1μg/mL
oligomycin plus 0.2μM FCCP were added and oxygen consumption was
supported by 10mM glutamate plus 5mM malate. Since the control and
1μM simvastatin bars were not statically different in Figure 1 and panel
(A), we used a general averages for controls and 1μM simvastatin in both
figures. ∗p < 0.05 vs control by one-way analysis of variance. N = at least
6 independent experiments.
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FIGURE 4 | Increase in lactate production by 1µM simvastatin was
prevented by mevalonate, Co-Q10 or L-carnitine in skeletal muscle.
An aliquot of MiR05 medium containing non-permeabilized skeletal
muscle samples pre incubated by 1 h with 1μM simvastatin or
DMSO, or coincubated with 100μM mevalonate, 10μM coenzyme
Q10 or 1mM L-carnitine was added to a medium containing 50mM
hidroxilamine, 50mM tris, 800μM NAD+, 40U lactate dehydrogenase,
pH 10 at 25◦C, for spectrofluorimetric assay of lactate release.
∗p < 0.05 vs. control by one-way analysis of variance. N = at least
5 independent experiments.
cells against simvastatin induced toxicity (Arduini et al., 2004;
Costa et al., 2013). Figures 3A,B, respectively, show that 1mM
L-carnitine protected against inhibition of complex I respiration
stimulated by ADP or FCCP.
INCREASE IN LACTATE PRODUCTION BY 1µM SIMVASTATINWAS
PREVENTED BY MEVALONATE, Co-Q10 OR L-carnitine IN SKELETAL
MUSCLE FIBERS
Treatment of hypercholesterolemic patients with statins has been
reported (De Pinieux et al., 1996) to increase lactate/pyruvate
ratio in blood serum. In fact, this ratio can be used as a non-
invasive test to detect impairment or toxic effects on mitochon-
drial energy linked metabolism (Robinson, 1989; Munnich et al.,
1992; Chariot et al., 1994). Here we present data showing that
1 h incubation of skeletal muscle tissue with 1μM simvastatin
caused an increase of 26% in lactate production (Figure 4) that
was abolished by the co-incubation of simvastatin with each of
the compounds 100μM mevalonate, 10μM Co-Q10, or 1mM
L-carnitine.
DECREASE IN COENZYME Q10 BY 1µM SIMVASTATINWAS
PREVENTED BY MEVALONATE BUT NOT BY L-carnitine IN SKELETAL
MUSCLE FIBERS
In order to ascertain the possible role of ubiquinone in the mech-
anism of statins induced mitochondrial dysfunction (Ghirlanda
et al., 1993; Laaksonen et al., 1995; Thibault et al., 1996; Miyake
et al., 1999; Rundek et al., 2004; Paiva et al., 2005; Littarru and
Tiano, 2010) we assayed the Co-Q10 content in permeabilized
skeletal muscle tissues after 1 h incubation with 1μMsimvastatin.
Figure 5 shows that under the same experimental conditions in
which the statin promotes inhibition of respiration the reduced
FIGURE 5 | Determination of coenzyme Q10 in skeletal muscle
incubated with 1µM simvastatin alone or in the presence of
mevalonate or L-carnitine. Permeabilized skeletal muscle samples were
incubated in MiR05 medium in the presence of 1μM simvastatin, or
DMSO for 1 h in the presence of 100μM mevalonate, 10μM coenzyme
Q10, or 1mM L-carnitine. After tissue homogenization, extraction was
performed utilizing perchloric acid and cold methanol. Coenzyme Q10 was
measured with a Shimadzu HPLC. ∗p < 0.05 vs. control by one-way
analysis of variance. N = at least 9 independent experiments.
levels of Co-Q10 were about 40% decreased relative to the con-
trol experiment. Interestingly, 100μM mevalonate but not 1mM
L-carnitine prevented the decrease in Co-Q10 content. Therefore,
we hypothesized that either L-carnitine or Co-Q10 protected
against simvastatin-induced inhibition of respiration by acting as
antioxidants. Accordingly, this inhibition of respiration was not
mediated by the ability of Co-Q10 to transfer electrons from com-
plex I and II to complex III, but rather by the action of Co-Q10
as a free radical scavenger. In order to ascertain this possibility
we next investigated the effects of simvastatin alone or in co-
incubation with 100μM mevalonate, 10μM Co-Q10, or 1mM
L-carnitine on hydrogen peroxide production by skeletal muscle
fibers mitochondria.
INCREASE IN HYDROGEN PEROXIDE BY 1µM SIMVASTATINWAS
PREVENTED BY MEVALONATE, Co-Q10 OR L-carnitine IN SKELETAL
MUSCLE FIBERS
Literature data also report that statin treatment may increase the
rates of superoxide and hydrogen peroxide production in muscu-
lar cells (Kwak et al., 2012) and in muscle tissues from patients
(Bouitbir et al., 2012b). In this study we assayed hydrogen perox-
ide and found that 1 h incubation of skeletal muscle tissues with
1μM simvastatin promoted an increase of about 103% in the
rate of hydrogen peroxide production compared to the controls.
Similarly to what happens with respiration and lactate produc-
tion, this increase in H2O2 was abolished by co-incubation of
simvastatin with 100μM mevalonate, 10μM Co-Q10, or 1mM
L-carnitine (Figure 6).
DISCUSSION
The present work provides evidence that 1 h incubation of skele-
tal muscle fibers with 1μM simvastatin promotes mitochondrial
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FIGURE 6 | Increase in hydrogen peroxide release by 1µM simvastatin
was prevented by mevalonate, Co-Q10 or L-carnitine in skeletal
muscle. Permeabilized skeletal muscle samples were incubated, for 1 h, in
medium MiR05 containing 1μM simvastatin or DMSO, 10μM Amplex red,
1 U/mL horseradish peroxidase, 10mM glutamate, 5mM malate, or
simultaneous incubated with 100μM mevalonate, 10μM coenzyme Q10 or
1mM L-carnitine. Changes in fluorescence were monitored on a
spectrofluorometer. ∗p < 0.05 vs. control by one-way analysis of variance.
N = at least 5 independent experiments.
dysfunction associated with inhibition of respiration, decrease in
the content of Co-Q10 and increased rates of hydrogen peroxide
production.
Most literature data on statins toxicity was obtained from
in vivo or in vitro experiments using different animal models
and higher doses than those found in the serum of hyperc-
holesterolemic patients (Sacher et al., 2005; Sirvent et al., 2005a;
Kaufmann et al., 2006; Nadanaciva et al., 2007). Here we ana-
lyzed the mechanisms underlying mitochondrial dysfunctions
associated with the lowest simvastatin concentration (1μM) that
significantly inhibited respiration supported by complex I and II
linked substrates, under our experimental conditions. Although
the assays were made in vitro using muscle biopsies, the present
findings may be relevant to the understanding of statins toxicity
in vivo that produces a variety of myophatic symptoms includ-
ing myalgia, muscle cramps, and rarely rhabdomyolysis. These
symptoms are more frequent in patients treated with high statin
doses (80mg/daily) and are increased by factors or conditions
that increase serum and muscle statin concentrations (grape fruit
juice, hypothyroidism, diabetes mellitus, advanced age, liver, and
kidney diseases), and factors that increase muscle susceptibility to
injury such as alcohol consumption, drug abuse, heavy exercise,
and some muscle diseases (Venero and Thompson, 2009).
In the present study we did not find significant difference
in resting respiration between statin treatment and controls. In
contrast, a significant inhibition of both phosphorylating and
uncoupled respiration, relative to the controls (Figure 1) suggests
that mitochondrial number and density were normal and that the
maximal respiratory capacity of skeletal muscle was decreased by
simvastatin. This interpretation is supported by the citrate syn-
thase assay (Figure 2) and is in line with those by Kwak et al.
(2012) using myotube cells treated with simvastatin.
Increase in lactate levels, decrease in ATP production, and
stimulated glycolysis have also been associated with inhibition of
muscle respiration by statins impairment of mitochondrial func-
tions (Robinson, 1989; Munnich et al., 1992; Chariot et al., 1994).
Here we show that both inhibition of respiration and increase
in lactate production were prevented by co-incubation of sim-
vastatin with L-carnitine, mevalonate or Co-Q10; compounds
known to protect against statins toxicity (Arduini et al., 2004;
Sacher et al., 2005; Kettawan et al., 2007; Oliveira et al., 2008;
Costa et al., 2013). These results are consistent with literature
data (Kaufmann et al., 2006; Sirvent et al., 2008) proposing that
simvastatin-induced inhibition of oxygen consumption in skeletal
muscle is mediated by inhibition of Co-Q10 synthesis. On these
grounds, the present results suggest that L-carnitine might also be
protecting against the decrease in Co-Q10.
Co-Q10 is a mobile carrier that collects electrons from com-
plex I and II transferring them to complex III and, in addition,
in its reduced form (ubiquinol) acts as a potent antioxidant
(Graham et al., 2009; Deichmann et al., 2010; Figueira et al.,
2013). Supplementation with Co-Q10 has demonstrated effec-
tiveness in ameliorating neurodegenerative diseases, cerebellar
ataxia, heart failure, and muscular symptoms (Kaikkonen et al.,
2002; Naini et al., 2003; Mabuchi et al., 2007; Littarru and Tiano,
2010). Therefore, we assayed the Co-Q10 content in skeletal
muscle tissue treated with 1μM simvastatin. In agreement with
literature data (Ghirlanda et al., 1993; Laaksonen et al., 1995;
Thibault et al., 1996; Miyake et al., 1999; Rundek et al., 2004;
Paiva et al., 2005; Littarru and Langsjoen, 2007) our results indi-
cate that simvastatin significantly decreased the content of the
reduced form of Co-Q10. Interestingly, the co-incubation with
L-carnitine, in contrast to the co-incubation withmevalonate that
also protects against simvastatin-induced inhibition of respira-
tion, did not protect against Co-Q10 depletion. This indicates that
the decreased content of Co-Q10 is limiting the rate of mitochon-
drial respiration in the presence of simvastatin mainly due to its
property to remove or scavenging free radicals and not due to its
property to transfer electrons from complexes I and II to com-
plex III. As a matter of fact, Panov et al. (2005) provided evidence
that inhibition of respiration by superoxide, at the levels of com-
plex I and complex II, may result from damage to 4Fe-4S clusters.
Indeed, complex I has six and complex II has one 4Fe-4S clusters
rendering these structures highly sensitive to the damaging effects
of superoxide. Accordingly, previous data indicate that enzymes
containing 4Fe-4S clusters are particularly vulnerable to damag-
ing by superoxide or peroxinitrite radicals (Flint et al., 1993; Radi
et al., 1994; Fridovich, 1995; Bouton et al., 1996; Panov et al.,
2005; Demicheli et al., 2007).
L-carnitine is known to protect against mitochondrial dys-
functions associated with oxidative stress caused by a series of
conditions such as aging, ischemia reperfusion, inflammation,
degenerative diseases, carcinogenesis and drug toxicity, in vivo
or in vitro (Moretti et al., 2002; Binienda, 2003; Kumaran
et al., 2004, 2005; Sener et al., 2004; Virmani et al., 2004;
Binienda et al., 2005; Keil et al., 2006; Yapar et al., 2007; Shen
et al., 2008; Silva-Adaya et al., 2008; Elinos-Calderon et al.,
2009; Vamos et al., 2010; Ye et al., 2010; Zhang et al., 2010).
Given the properties of L-carnitine to scavenge reactive oxygen
Frontiers in Physiology | Mitochondrial Research May 2013 | Volume 4 | Article 103 | 6
La Guardia et al. Statins-induced mitochondrial dysfunction
(Gulcin, 2006; Mescka et al., 2011) and to bind Fe2+ (Gulcin,
2006), we propose that this molecule may directly interact with
4Fe-4S clusters protecting the respiratory complexes I and II
against the attack by the superoxide radical. This proposition is
not in contrast to the results reported by Benati et al. (2010)
showing that simvastatin decreases the capacity of macrophages
to phagocyte and kill bacteria by impairment of oxidative burst,
a rather different mechanism not involving the mitochondrial
respiratory chain.
In addition, it is noteworthy to remind that 60μM
simvastatin-induced MPT and cell necrosis were sensitive to
L-carnitine or piracetam in a dose-dependent fashion and medi-
ated by additive mechanisms (Costa et al., 2013). In the present
work we observed that piracetam did not affect the inhibition
of respiration or the increase in H2O2 production induced by
1μM simvastatin (results not shown). These results suggest that
in the previous work (Costa et al., 2013) the role of pirac-
etam on the protection against high simvastatin concentrations
(60μM) was mediated by the ability of the compound to pro-
tect against Ca2+-induced alterations in membrane fluidity (Keil
et al., 2006). This occurs via unspecific interactions of pirac-
etam with the polar head groups of biological membranes (Keil
et al., 2006). Indeed, Ca2+ binding to innermembrane cardiolipin
causes important alterations in the lipid organization that favors
the burst of mitochondrial ROS that triggers Ca2+-induced MPT
(Grijalba et al., 1999).
CONCLUSIONS
Considering that the three compounds (mevalonate, Co-Q10, or
L-carnitine) that prevented the inhibition of respiration by sim-
vastatin also protected against stimulation of hydrogen peroxide
generation, we may conclude that reactive oxygen is the com-
mon denominator in the mechanism of respiration inhibition
by statins. In addition, the lack of protection against Co-Q10
depletion by L-carnitine indicates that this compound as well
as Co-Q10 acts directly as radical scavenger in the protection
against simvastatin-induced oxidative damage to skeletal muscle
mitochondria.
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